OM · Insider Trading
Outset Medical, Inc. Common Stock
Every open-market purchase and sale reported by OM officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-05 | Braden Michael Leonard | 10%+ Owner | Buy | +244,909 | +$870.26K |
| 2026-08-18 | Leslie Trigg | Chair and CEO | Sell | −3,437 | −$15.09K |
| 2026-08-18 | Renee Gaeta | Chief Financial Officer | Sell | −4,543 | −$19.94K |
| 2026-08-18 | John L. Brottem | General Counsel | Sell | −2,632 | −$11.55K |
| 2026-06-29 | Renee Gaeta | Chief Financial Officer | A | +71,630 | — |
| 2026-06-29 | John L. Brottem | General Counsel | A | +59,830 | — |
| 2026-06-29 | Leslie Trigg | Chair and CEO | A | +99,160 | — |
| 2026-06-05 | Kevin C Oboyle | Director | A | +10,667 | — |
| 2026-06-05 | Karen Prange | Director | A | +10,667 | — |
| 2026-06-05 | Renee Gaeta | Chief Financial Officer | Sell | −17,672 | −$87.30K |
| 2026-06-05 | D Keith Grossman | Director | A | +10,667 | — |
| 2026-06-05 | Brent D. Lang | Director | A | +10,667 | — |
| 2026-06-05 | Patrick T Hackett | Director | A | +10,667 | — |
| 2026-06-05 | Karen Drexler | Director | A | +10,667 | — |
| 2026-05-19 | Leslie Trigg | Chair and CEO | Sell | −3,445 | −$12.75K |
| 2026-05-19 | Marc Nash | EVP Operations R&D & Service | Sell | −1,582 | −$5.85K |
| 2026-05-19 | John L. Brottem | General Counsel | Sell | −2,638 | −$9.76K |
| 2026-05-18 | Braden Michael Leonard | 10%+ Owner | X | +323,000 | +$1.61M |
| 2026-05-12 | Braden Michael Leonard | 10%+ Owner | X | +294,500 | +$1.47M |
| 2026-04-08 | Derick A. Elliott | EVP, Commercial | A | +96,000 | — |
| 2026-02-19 | Marc Nash | EVP Operations R&D & Service | Sell | −1,817 | −$6.09K |
| 2026-02-19 | John L. Brottem | General Counsel | Sell | −2,842 | −$9.52K |
| 2026-02-19 | Leslie Trigg | Chair and CEO | Sell | −3,361 | −$11.26K |
| 2026-01-21 | John L. Brottem | General Counsel | Sell | −10,494 | −$53.60K |
| 2026-01-21 | Marc Nash | EVP Operations R&D & Service | Sell | −6,355 | −$32.40K |
| 2026-01-21 | Leslie Trigg | Chair and CEO | Sell | −13,914 | −$71.09K |
| 2026-01-12 | Karen Prange | Director | A | +18,667 | — |
| 2026-01-08 | John L. Brottem | General Counsel | Sell | −224 | −$956 |
| 2026-01-08 | Marc Nash | EVP Operations R&D & Service | Sell | −108 | −$461 |
| 2026-01-08 | Leslie Trigg | Chair and CEO | Sell | −1,795 | −$7.66K |
| 2025-12-02 | Karen Drexler | Director | Sell | −1,548 | −$6.76K |
| 2025-11-18 | Leslie Trigg | Chair and CEO | Sell | −916 | −$4.21K |
| 2025-11-18 | Marc Nash | EVP Operations R&D & Service | Sell | −247 | −$1.14K |
| 2025-11-18 | John L. Brottem | General Counsel | Sell | −388 | −$1.78K |
| 2025-08-25 | Marc Nash | EVP, R&D, Operations and Serv. | A | +5,617 | — |
| 2025-08-18 | Marc Nash | SVP Operations and R&D | Sell | −243 | −$3.13K |
| 2025-08-18 | John L. Brottem | General Counsel | Sell | −383 | −$4.93K |
| 2025-08-18 | Leslie Trigg | Chair and CEO | Sell | −904 | −$11.64K |
| 2025-06-11 | John L. Brottem | General Counsel | A | +35,993 | — |
| 2025-06-11 | Marc Nash | SVP Operations and R&D | A | +29,676 | — |
| 2025-06-11 | Renee Gaeta | Chief Financial Officer | A | +131,425 | — |
| 2025-06-11 | Leslie Trigg | Chair and CEO | A | +65,103 | — |
| 2025-06-04 | D Keith Grossman | Director | A | +8,983 | — |
| 2025-06-04 | Andrea Lynn Saia | Director | A | +8,983 | — |
| 2025-06-04 | Kevin C Oboyle | Director | A | +8,983 | — |
| 2025-06-04 | Karen Drexler | Director | A | +8,983 | — |
| 2025-06-04 | Patrick T Hackett | Director | A | +8,983 | — |
| 2025-06-04 | Brent D. Lang | Director | A | +8,983 | — |
| 2025-05-16 | John L. Brottem | General Counsel | Sell | −396 | −$7.06K |
| 2025-05-16 | Marc Nash | SVP Operations and R&D | Sell | −252 | −$4.49K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Braden Michael Leonard | 10%+ Owner | 2,764,610 | $11.28M |
| Leslie Trigg | Chair and CEO | 195,181 | $796.34K |
| Patrick T Hackett | Director | 189,172 | $771.82K |
| Renee Gaeta | Chief Financial Officer | 180,840 | $737.83K |
| Derick A. Elliott | EVP, Commercial | 96,000 | $391.68K |
| John L. Brottem | General Counsel | 87,475 | $356.90K |
| Brent D. Lang | Director | 45,184 | $184.35K |
| Marc Nash | EVP Operations R&D & Service | 38,393 | $156.64K |
| D Keith Grossman | Director | 37,430 | $152.71K |
| Kevin C Oboyle | Director | 34,785 | $141.92K |
| Karen Prange | Director | 29,334 | $119.68K |
| Karen Drexler | Director | 23,400 | $95.47K |
| Nabeel Ahmed | Chief Financial Officer | 16,096 | $65.67K |
| Andrea Lynn Saia | Director | 12,175 | $49.67K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the OM quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.